Ten-Hour Time-Restricted Eating Reduces Weight, Blood Pressure, and Atherogenic Lipids in Patients with Metabolic Syndrome.
Antihypertensive Agents
/ therapeutic use
Blood Cell Count
Blood Glucose
/ metabolism
Blood Pressure
Body Weight
Circadian Rhythm
/ physiology
Diabetes Mellitus, Type 2
/ diet therapy
Exercise
/ physiology
Fasting
/ blood
Female
Follow-Up Studies
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ therapeutic use
Lipid Metabolism
/ physiology
Lipids
/ blood
Male
Metabolic Syndrome
/ diet therapy
Middle Aged
Obesity
Sleep
/ physiology
TRE
TRF
circadian rhythm
dyslipidemia
hypertension
impaired glucose tolerance
metabolic syndrome
obesity
time-restricted eating
Journal
Cell metabolism
ISSN: 1932-7420
Titre abrégé: Cell Metab
Pays: United States
ID NLM: 101233170
Informations de publication
Date de publication:
07 01 2020
07 01 2020
Historique:
received:
29
05
2019
revised:
20
09
2019
accepted:
08
11
2019
pubmed:
10
12
2019
medline:
13
5
2021
entrez:
10
12
2019
Statut:
ppublish
Résumé
In animal models, time-restricted feeding (TRF) can prevent and reverse aspects of metabolic diseases. Time-restricted eating (TRE) in human pilot studies reduces the risks of metabolic diseases in otherwise healthy individuals. However, patients with diagnosed metabolic syndrome often undergo pharmacotherapy, and it has never been tested whether TRE can act synergistically with pharmacotherapy in animal models or humans. In a single-arm, paired-sample trial, 19 participants with metabolic syndrome and a baseline mean daily eating window of ≥14 h, the majority of whom were on a statin and/or antihypertensive therapy, underwent 10 h of TRE (all dietary intake within a consistent self-selected 10 h window) for 12 weeks. We found this TRE intervention improves cardiometabolic health for patients with metabolic syndrome receiving standard medical care including high rates of statin and anti-hypertensive use. TRE is a potentially powerful lifestyle intervention that can be added to standard medical practice to treat metabolic syndrome. VIDEO ABSTRACT.
Identifiants
pubmed: 31813824
pii: S1550-4131(19)30611-4
doi: 10.1016/j.cmet.2019.11.004
pmc: PMC6953486
mid: NIHMS1545257
pii:
doi:
Substances chimiques
Antihypertensive Agents
0
Blood Glucose
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Lipids
0
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
92-104.e5Subventions
Organisme : NCI NIH HHS
ID : P30 CA014195
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK115214
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK118278
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Références
Obes Rev. 2016 Oct;17(10):1001-11
pubmed: 27324830
Circulation. 2017 Feb 28;135(9):e96-e121
pubmed: 28137935
Proc Nutr Soc. 2016 Nov;75(4):475-486
pubmed: 27327128
Sci Transl Med. 2017 Feb 15;9(377):
pubmed: 28202779
Diabetes Technol Ther. 2015 Nov;17(11):787-94
pubmed: 26171659
Sci Total Environ. 2017 Dec 31;607-608:1073-1084
pubmed: 28724246
J Clin Lipidol. 2015 Nov-Dec;9(6 Suppl):S1-122.e1
pubmed: 26699442
Cancer Epidemiol Biomarkers Prev. 2018 Jan;27(1):25-40
pubmed: 29311165
Mil Med. 2011 Jul;176(7):811-6
pubmed: 22128724
Circulation. 2011 May 24;123(20):2292-333
pubmed: 21502576
Obesity (Silver Spring). 2019 May;27(5):724-732
pubmed: 31002478
Cell Metab. 2018 Jun 05;27(6):1212-1221.e3
pubmed: 29754952
Eur J Sport Sci. 2017 Mar;17(2):200-207
pubmed: 27550719
J Am Coll Cardiol. 2015 Sep 1;66(9):1050-67
pubmed: 26314534
Int J Occup Med Environ Health. 2012 Sep;25(4):383-91
pubmed: 23055229
Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16647-53
pubmed: 25404320
Am J Prev Med. 2013 Apr;44(4 Suppl 4):S324-32
pubmed: 23498294
J Transl Med. 2016 Oct 13;14(1):290
pubmed: 27737674
PLoS One. 2017 Mar 6;12(3):e0172852
pubmed: 28264001
Am J Med. 1995 Feb;98(2):115-7
pubmed: 7847427
Am J Public Health. 2015 Nov;105(11):2328-34
pubmed: 26378828
Science. 2015 Mar 13;347(6227):1265-9
pubmed: 25766238
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Sleep Health. 2015 Dec;1(4):233-243
pubmed: 29073398
Appl Physiol Nutr Metab. 2019 Jan;44(1):107-109
pubmed: 30216730
Natl Health Stat Report. 2009 May 5;(13):1-7
pubmed: 19634296
Cell. 2015 Mar 26;161(1):84-92
pubmed: 25815987
Obesity (Silver Spring). 2008 Jun;16(6):1302-7
pubmed: 18388902
Cell Metab. 2019 Aug 6;30(2):238-250
pubmed: 31390550
Lancet Diabetes Endocrinol. 2014 Mar;2(3):218-27
pubmed: 24622752
Circulation. 2010 Feb 2;121(4):586-613
pubmed: 20089546
Public Health Nutr. 2016 Mar;19(4):667-73
pubmed: 25936413
Trends Endocrinol Metab. 2016 Feb;27(2):69-83
pubmed: 26706567
Br J Nutr. 2013 Dec 14;110(11):2108-13
pubmed: 23702187
Nutr Healthy Aging. 2018 Jun 15;4(4):345-353
pubmed: 29951594
Metabolism. 2016 Dec;65(12):1743-1754
pubmed: 27832862
Cell Metab. 2015 Nov 3;22(5):789-98
pubmed: 26411343
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
Cell Metab. 2014 Dec 2;20(6):991-1005
pubmed: 25470547
Science. 2016 Nov 25;354(6315):1008-1015
pubmed: 27885007
Trends Pharmacol Sci. 2018 Sep;39(9):812-827
pubmed: 30060890
Scand J Work Environ Health. 2010 Mar;36(2):96-108
pubmed: 20087536